Literature DB >> 21997597

Severe immune hemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer.

Xiaojiang Sun1, Liming Sheng, Qinghua Deng, Peng Liu, Ke Lu.   

Abstract

Pemetrexed-induced immune hemolytic anemia is a rare acute complication and a potentially life-threatening syndrome. Here we report a case of severe hemolytic anemia induced by pemetrexed in a 67-year-old man with lung adenocarcinoma. Hemoglobin concentration reached a nadir of 6.8 g/dl after 6 days of pemetrexed initiation. Pemetrexed was discontinued and the patient was given a transfusion of red blood cells. The direct antiglobulin test was positive (anti-IgG = 4+, anti-C3d = 2+). The patient's plasma reacted with pemetrexed-treated red blood cells by the immune complex test.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997597     DOI: 10.1159/000331866

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  3 in total

Review 1.  Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: a case report and review of literature.

Authors:  Yaya Wang; Bailu Xie; Yu Chen; Zhenqian Huang; Huo Tan
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

2.  Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed.

Authors:  Irene Alabiso; Chiara Baratelli; Maria Pia Brizzi; Raffaella Bitossi; Azzurra Ottone; Marco Tampellini
Journal:  Int J Clin Pharm       Date:  2014-11-05

3.  Case report: First case of pemetrexed plus cisplatin-induced immune hemolytic anemia in a patient with lung adenocarcinoma.

Authors:  Hongkai Lu; Na Wang; Peng Wang; Haolin Zhang; Ru Zhao; Hongju Liu; Xirong He; Zeya Liu; Yue Chang; Yongtong Cao; Shiyao Wang
Journal:  Front Med (Lausanne)       Date:  2022-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.